{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:39:54Z","timestamp":1792773594514,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101136953 (DEFINITIVE)"],"award-info":[{"award-number":["101136953 (DEFINITIVE)"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108345","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:32Z","timestamp":1786119332000},"page":"108345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3734","authenticated-orcid":false,"given":"N.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"DeMichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-8626","authenticated-orcid":false,"given":"J.M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0236","authenticated-orcid":false,"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Waks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-8196","authenticated-orcid":false,"given":"K.","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Llombart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8592-2239","authenticated-orcid":false,"given":"P.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2026.108345_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108345_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108345_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108345_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108345_bib5","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s12094-023-03203-8","article-title":"SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)","volume":"25","author":"Garcia-Saenz","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.108345_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/EDBK_175630","article-title":"Optimal management of early and advanced HER2 breast cancer","volume":"37","author":"Hurvitz","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108345_bib7","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s12094-024-03409-4","article-title":"Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey","volume":"26","author":"Mart\u00ednez-S\u00e1ez","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108345_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108345_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108345_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108345_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","article-title":"Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab","volume":"9","author":"Waks","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108345_bib11","article-title":"Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study","volume":"8","author":"Mart\u00ednez-S\u00e1ez","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108345_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2025.43.16_suppl.607","article-title":"HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): final analysis from the BiOnHER clinical trial","volume":"43","author":"Grimalt","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108345_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12094-025-04139-x","article-title":"SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)","volume":"28","author":"de la Pe\u00f1a","year":"2026","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108345_bib16","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108345_bib18","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.02170","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2-positive breast cancer: 5-year results and correlative analyses from ATEMPT","volume":"42","author":"Tarantino","year":"2024","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2026.108345_bib19","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.20.00184","article-title":"Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients","volume":"38","author":"Sawaki","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib20","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1038\/s41467-025-65599-x","article-title":"HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab \u00b1 chemotherapy","volume":"16","author":"Nozawa","year":"2025","journal-title":"Nat Commun"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2026.108345_bib21","article-title":"Abstract PS09-02: Event-free survival by residual cancer burden (RCB) and intratumor HER2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer","volume":"84","author":"Metzger","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108345_bib22","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","article-title":"HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from PHERGain phase II trial","volume":"30","author":"Llombart-Cussac","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108345_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2023.0187","article-title":"Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab","volume":"9","author":"Bueno-Mui\u00f1o","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1158\/1078-0432.CCR-25-3123","article-title":"Associations of the HER2DX genomic test with biological and pathologic features in HER2-positive breast cancer","volume":"32","author":"Sanfeliu","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108345_bib25","first-page":"GS1","article-title":"Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181\/CompassHER2 pCR trial","volume":"32","author":"Badve","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108345_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108345_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104100","article-title":"HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers","volume":"10","author":"Lynce","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108345_bib28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdz055","article-title":"De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","volume":"30","author":"Guarneri","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108345_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105823","article-title":"Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+\/HER2+ early breast cancer: a POETIC translational study","volume":"118","author":"Sirv\u00e9n","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.esmoop.2026.108345_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104320","article-title":"HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial","volume":"85","author":"Guarneri","year":"2022","journal-title":"EBioMedicine"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108345_bib31","article-title":"13P A novel H&E-based classification of tertiary lymphoid structures in breast cancer","volume":"10","author":"Solis","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104109","article-title":"Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer","volume":"10","author":"Angelats","year":"2025","journal-title":"ESMO Open"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108345_bib33","article-title":"7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer","volume":"8","author":"Torres","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102388","article-title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network Breast dataset (SCAN-B)","volume":"9","author":"Villacampa","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2026.108345_bib36","first-page":"PS4","article-title":"PS4-06: HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab and pertuzumab: correlative analysis from CLEOPATRA phase III trial","volume":"31","author":"Cort\u00e9s","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108345_bib37","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.108345_bib38","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.3390\/ijms27125293","article-title":"Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer","volume":"27","author":"Nogueira","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108345_bib39","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108345_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100088","article-title":"Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis","volume":"6","author":"Peleg Hasson","year":"2021","journal-title":"ESMO Open"},{"issue":"10191","key":"10.1016\/j.esmoop.2026.108345_bib41","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"issue":"10191","key":"10.1016\/j.esmoop.2026.108345_bib42","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(19)30946-8","article-title":"Is the duration of adjuvant trastuzumab debate still clinically relevant?","volume":"393","author":"Hurvitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00060-2","article-title":"6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting","volume":"23","author":"Becerra-Chauca","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib44","article-title":"Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data","volume":"4","author":"Earl","year":"2025","journal-title":"BMJ Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jnci\/djac227","article-title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","volume":"115","author":"Bras\u00f3-Maristany","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108345_bib46","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/cncr.34750","article-title":"Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts","volume":"129","author":"Weiss","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108345_bib49","article-title":"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial","volume":"43","author":"Gao","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108345_bib50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108345_bib51","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108345_bib52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108345_bib53","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108345_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108345_bib56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41698-026-01365-6","article-title":"Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer","volume":"10","author":"Tarantino","year":"2026","journal-title":"NPJ Precis Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108345_bib58","article-title":"PS4-01-07: Prospective validation of HER2DX in early HER2+ breast cancer: operational feasibility of centralized genomic screening in the DEFINITIVE trial. Real-time insights from the first 80 screened patients","volume":"32","author":"Gonzalez Rodriguez","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108345_bib64","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.2217\/fon-2021-0753","article-title":"Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib\/placebo in patients with residual HER2-positive invasive breast cancer","volume":"17","author":"O\u2019Sullivan","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.108345_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108345_bib60","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","article-title":"Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors","volume":"16","author":"Magbanua","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108345_bib61","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1200\/JCO-25-02934","article-title":"The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease","volume":"44","author":"Hunter","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108345_bib62","first-page":"GS1","article-title":"GS1-06: Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC): translational analysis of PHERGain neoadjuvant tailored treatment study","volume":"32","author":"Llombart-Cussac","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108345_bib63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:40:31Z","timestamp":1792770031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022878"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108345","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108345"}}